Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus.
Benjamin BurggraafNadine M C PouwSalvador Fernández ArroyoLeonie C van Vark-van der ZeeGert-Jan M van de GeijnErwin BirnieJeannine HuisbrinkEllen M van der ZwanWouter W de HerderMonique T MulderPatrick C N RensenManuel Castro CabezasPublished in: European journal of endocrinology (2022)
Treatment with dapagliflozin of patients with T2DM led to a reduction of fasting chylomicron remnants and increased postprandial ketone bodies compared to placebo suggesting enhanced hepatic fatty acid oxidation. The latter may have been caused by decreasing the insulin-glucagon ratio. The beneficial clinical effects seen in the trials using dapagliflozin most likely are not due to effects on postprandial inflammation nor postprandial lipemia.